よむ、つかう、まなぶ。
資料3-1 リツキシマブ（遺伝子組換え） (51 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00026.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第54回 2／15）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-64.
19） Boletis JN, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus
nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24: 2157-60.
20） Trachana M, et al. Safety and efficacy of rituximab in refractory pediatric systemic lupus
erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013; 33:
809-13.
21） Baskin E, et al. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in
childhood lupus nephritis. Pediatr Nephrol 2010; 25: 111-7.
22） Rovin BH, et al. Efficacy and safety of rituximab in patients with active proliferative lupus
nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:
1215-26.
23） Bang SY, et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in
korean patients with refractory systemic lupus erythematosus. Autoimmune Dis 2012; 2012:
565039.
24） Watson L, et al. The indications, efficacy and adverse events of rituximab in a large cohort of
patients with juvenile-onset SLE. Lupus 2015; 24: 10-7.
25） Moroni G, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction
therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014; 53: 1570-7.
26） Condon MB, et al. Prospective observational single-centre cohort study to evaluate the
effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral
steroids. Ann Rheum Dis 2013; 72: 1280-6.
27） Tsanyan ME, et al. Clinical and morphological improvement of lupus nephritis treated with
rituximab. Folia Med 2014; 56: 245-52.
28） Vigna-Perez M, et al. Clinical and immunological effects of Rituximab in patients with lupus
nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.
29） Goswami RP, et al. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus
Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. J Clin Rheumatol
2019; 25: 28-35.
30） Melander C, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term
renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-87.
31） Garcia-Carrasco M, et al. Anti-CD20 therapy in patients with refractory systemic lupus
erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010; 19: 213-9.
32） Li EK, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the
treatment of lupus nephritis? Rheumatology 2009; 48: 892-8.
33） Pepper R, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction
in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-23.
34） Contis A, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory
51
19） Boletis JN, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus
nephritis: a long-term prospective study. Nephrol Dial Transplant 2009; 24: 2157-60.
20） Trachana M, et al. Safety and efficacy of rituximab in refractory pediatric systemic lupus
erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013; 33:
809-13.
21） Baskin E, et al. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in
childhood lupus nephritis. Pediatr Nephrol 2010; 25: 111-7.
22） Rovin BH, et al. Efficacy and safety of rituximab in patients with active proliferative lupus
nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:
1215-26.
23） Bang SY, et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in
korean patients with refractory systemic lupus erythematosus. Autoimmune Dis 2012; 2012:
565039.
24） Watson L, et al. The indications, efficacy and adverse events of rituximab in a large cohort of
patients with juvenile-onset SLE. Lupus 2015; 24: 10-7.
25） Moroni G, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction
therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014; 53: 1570-7.
26） Condon MB, et al. Prospective observational single-centre cohort study to evaluate the
effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral
steroids. Ann Rheum Dis 2013; 72: 1280-6.
27） Tsanyan ME, et al. Clinical and morphological improvement of lupus nephritis treated with
rituximab. Folia Med 2014; 56: 245-52.
28） Vigna-Perez M, et al. Clinical and immunological effects of Rituximab in patients with lupus
nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.
29） Goswami RP, et al. Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus
Nephritis Remission Induction: A Historical Head-to-Head Comparative Study. J Clin Rheumatol
2019; 25: 28-35.
30） Melander C, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term
renal outcome. Clin J Am Soc Nephrol 2009; 4: 579-87.
31） Garcia-Carrasco M, et al. Anti-CD20 therapy in patients with refractory systemic lupus
erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus 2010; 19: 213-9.
32） Li EK, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the
treatment of lupus nephritis? Rheumatology 2009; 48: 892-8.
33） Pepper R, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction
in maintenance steroids. Nephrol Dial Transplant 2009; 24: 3717-23.
34） Contis A, et al. Analysis of the effectiveness and safety of rituximab in patients with refractory
51